Epidermicin is an exciting innovation that can be used to prevent and treat infections caused by hospital ‘superbugs’ like MRSA. This first in class antimicrobial demonstrated high efficiency in infection models: research showed that a single dose of Epidermicin is as active as six doses of current standard treatment. Epidermicin has very low levels of toxicity. It has recently completed pre-clinical evaluation with no adverse effects observed. Topical use of Epidermicin to treat skin and other types of infection, including pneumonia, could reduce the need for systemic antibiotics. This would improve antibiotic stewardship and help reduce antimicrobial resistance (AMR), a leading threat to global health. Epidermicin is manufactured using a highly cost-effective production method that meets regulatory requirements. The company is currently working on developing an AI-machine learning approach to generate novel variants of Epidermicin with activity ‘tuned’ towards different target bacteria. Epidermicin can become a leading agent in the prevention and treatment of devastating infections caused by bacteria high on the WHO list of priority pathogens.